SAN FRANCISCO – One of the hottest tickets in town Wednesday at the 36th Annual J.P. Morgan Healthcare Conference took place far from the hallways of the Westin St. Francis, as Women in Bio and Bloomberg Intelligence hosted an all-female panel of investors and industry executives who discussed the capital markets and their impact on biopharma development and commercialization. Read More
SAN FRANCISCO – Little more than five minutes' drive from Botox-maker Allergan plc's chief research center in Irvine, Calif., Evolus Inc. is prepping for a $75 million IPO that, if successful, could create new competition for the botulinum toxin king. Read More
SAN FRANCISCO – Exuberance over China's ascendant biopharma sector formed a near-deafening roar at the 6th Annual Wuxi Global Forum Tuesday, where Ruyi He, chief scientist of the CFDA's Center for Drug Evaluation (CDE), spoke to the accelerating pace of the Republic's regulatory reform. Read More
The findings of a new study by Swedish and Chinese researchers into a novel photosensitization-based drug-release system could bring about broad changes in the delivery of cancer therapies, with millions of patients worldwide potentially benefitting from this research. Read More
HONG KONG – KBP Biosciences Co. Ltd. closed a $76 million series A financing to, among other things, advance its lead asset, KBP-5074, a mineralocorticoid receptor antagonist for cardiovascular disease entering phase IIb studies. The cash will also support moving its headquarters to the U.S. Read More
HONG KONG – Chinese biotech Zensun (Shanghai) Sci & Tech Co. Ltd., which focuses on innovative therapeutics for cardiovascular and energy metabolic diseases, has plans to raise about ¥500 million (US$76 million) from a consortium of investors, including a state-owned fund. Read More
Syndax Pharmaceuticals Inc., of Waltham, Mass., is collaborating with Genentech Inc., of South San Francisco, a unit of Roche Holding AG, to test Syndax's entinostat, a class I HDAC inhibitor, with Genentech's programmed cell death ligand 1 blocking antibody Tecentriq (atezolizumab) in patients with second-line hormone receptor positive, human epidermal growth factor receptor 2 negative metastatic breast cancer. Read More
Ampliphi Biosciences Corp., of San Diego, priced a public offering of 4 million shares of its common stock, offered at a price to the public of $1 per share, for gross proceeds of $4 million. Read More
Curevac AG, of Tubingen, Germany, said it plans to initiate clinical testing this year of four new messenger RNA products targeting infectious diseases and cancers. Read More
The U.S. House Energy and Commerce Committee released a report Wednesday with several recommendations for improving oversight of the 340B Drug Pricing Program that is intended to help eligible hospitals provide charity care through savings achieved on certain discounted drugs. Read More
